Gastrointestinal endoscopy最新文献_第2页

Weight loss medications: A new Pandora’s box? 减肥药物：新的潘多拉魔盒？

IF 6.7 1区医学

Gastrointestinal endoscopy Pub Date : 2024-11-01 DOI: 10.1016/j.gie.2024.05.018

引用次数: 0

Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during EGD 胰高血糖素样肽-1 受体激动剂对食管胃十二指肠镜检查中胃黏膜可见度和残留胃内容物的影响

IF 6.7 1区医学

Gastrointestinal endoscopy Pub Date : 2024-11-01 DOI: 10.1016/j.gie.2024.05.012

{"title":"Effects of glucagon-like peptide-1 receptor agonists on gastric mucosal visibility and retained gastric contents during EGD","authors":"","doi":"10.1016/j.gie.2024.05.012","DOIUrl":"10.1016/j.gie.2024.05.012","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in diabetes and obesity management. Although GLP-1RAs delay gastric emptying, their impact on visibility during EGD remains uncertain.</div></div><div><h3>Methods</h3><div>A 1:1 matched case-control study was conducted. Individuals undergoing EGD who were taking GLP-1RAs were matched to nonusers based on demographic characteristics and diabetes status. A validated scale (POLPREP) was used to determine gastric mucosal visibility scores.</div></div><div><h3>Results</h3><div>A total of 84 pairs (N = 168) were included. GLP-1RA users had significantly lower visibility scores, with a 2.42 times higher likelihood of lower scores compared with nonusers. In addition, GLP-1RA users had a higher incidence of retained gastric contents (13.1% vs 4.8%; adjusted odds ratio, 4.62; <em>P</em> = .025) and aborted procedures due to this issue. No anesthesia-related adverse events were observed.</div></div><div><h3>Conclusions</h3><div>GLP-1RA use at the time of endoscopy exhibited higher odds of lower gastric mucosal visibility scores, retained contents, and aborted procedures. Further research is warranted.</div></div>","PeriodicalId":12542,"journal":{"name":"Gastrointestinal endoscopy","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140957032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An unusual presentation of necrotizing pancreatitis 坏死性胰腺炎的不寻常表现

IF 6.7 1区医学

Gastrointestinal endoscopy Pub Date : 2024-11-01 DOI: 10.1016/j.gie.2024.06.023

引用次数: 0

Magnetic compression anastomosis for treatment of malignant complete esophageal stricture (with video) 治疗恶性完全性食管狭窄的磁压吻合术（附视频）。

IF 6.7 1区医学

Gastrointestinal endoscopy Pub Date : 2024-11-01 DOI: 10.1016/j.gie.2024.06.021

引用次数: 0

Titanium clip combined with rubber band–assisted ERCP cannulation of a hidden papilla within duodenal diverticula 钛夹结合橡皮筋辅助 ERCP 插管十二指肠憩室内的隐藏乳头。

IF 6.7 1区医学

Gastrointestinal endoscopy Pub Date : 2024-11-01 DOI: 10.1016/j.gie.2024.06.018

引用次数: 0

Editors 编辑

IF 6.7 1区医学

Gastrointestinal endoscopy Pub Date : 2024-11-01 DOI: 10.1016/S0016-5107(24)03515-6

引用次数: 0

ASGE Update ASGE 最新情况

IF 6.7 1区医学

Gastrointestinal endoscopy Pub Date : 2024-11-01 DOI: 10.1016/S0016-5107(24)03518-1

引用次数: 0

Regression of a rectal lesion in a patient with Lynch syndrome after treatment with pembrolizumab 林奇综合征患者接受 Pembrolizumab 治疗后直肠病变消退

IF 6.7 1区医学

Gastrointestinal endoscopy Pub Date : 2024-11-01 DOI: 10.1016/j.gie.2024.06.020

引用次数: 0

Adverse event of the procedure for prolapsed hemorrhoids: a rare case of anastomotic diverticulum with a giant fecaloma 痔疮脱垂手术的并发症：吻合口憩室伴巨大粪瘤的罕见病例。

IF 6.7 1区医学

Gastrointestinal endoscopy Pub Date : 2024-11-01 DOI: 10.1016/j.gie.2024.06.022

引用次数: 0

Safety of first surveillance colonoscopy at 12 months after piecemeal EMR of large nonpedunculated colorectal lesions 大的非梗阻性结直肠病变片状内镜粘膜切除术后 12 个月首次监测结肠镜检查的安全性。

IF 6.7 1区医学

Gastrointestinal endoscopy Pub Date : 2024-11-01 DOI: 10.1016/j.gie.2024.05.008

{"title":"Safety of first surveillance colonoscopy at 12 months after piecemeal EMR of large nonpedunculated colorectal lesions","authors":"","doi":"10.1016/j.gie.2024.05.008","DOIUrl":"10.1016/j.gie.2024.05.008","url":null,"abstract":"<div><h3>Background and Aims</h3><div>After piecemeal EMR (pEMR) of nonpedunculated colorectal lesions ≥20 mm, guidelines recommend first endoscopic surveillance at 6 months. However, initial surveillance at 12 months may be adequate for selected low-risk lesions and could save the cost, risk, and inconvenience of 1 surveillance examination.</div></div><div><h3>Methods</h3><div>This study retrospectively examined a prospectively collected database of all colorectal lesions referred to our center for endoscopic resection between August 2019 and April 2023. We report recurrence rates of patients with colorectal lesions ≥20 mm removed by pEMR who were assigned to 6-month first surveillance or to 12-month first surveillance (or assigned to a 6-month surveillance visit but did not return until after 10 months).</div></div><div><h3>Results</h3><div>There were 561 nonpedunculated lesions ≥20 mm that underwent first follow-up, including 490 lesions in 443 patients assigned to 6-month surveillance and 71 lesions in 65 patients assigned to 12-month surveillance. Lesions assigned to 12-month surveillance were smaller (mean size, 25.9 ± 6.1 mm vs 37.0 ± 17.4 mm), more likely serrated (63.4% vs 9.6%), and more often removed by cold pEMR (74.6% vs 20.4%). Twenty-nine lesions in 24 patients assigned to 6-month surveillance presented after 10 months, and their recurrence data were included in the group assigned to 12-month surveillance. Overall recurrence rates at 6 months and 12 months were 10.0% (46 of 461) and 10.0% (10 of 100), respectively. Mean recurrence sizes at 6 and 12 months were 10.9 ± 6.2 mm and 5.0 ± 3.1 mm, respectively. One patient in the 6-month surveillance group had cancer at the pEMR site, but no other recurrences at 6 or 12 months had either cancer or high-grade dysplasia.</div></div><div><h3>Conclusions</h3><div>Twelve-month surveillance seems acceptable for selected colorectal lesions ≥20 mm removed by pEMR. A randomized trial comparing initial 6-month versus 12-month surveillance is warranted for selected lesions.</div></div>","PeriodicalId":12542,"journal":{"name":"Gastrointestinal endoscopy","volume":null,"pages":null},"PeriodicalIF":6.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0